Kintara Therapeutics, Inc.
KTRA
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.79M | 4.78M | 4.58M | 5.11M | 5.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.45M | 9.42M | 10.63M | 13.11M | 14.80M |
| Operating Income | -8.45M | -9.42M | -10.63M | -13.11M | -14.80M |
| Income Before Tax | -8.32M | -9.33M | -10.58M | -13.02M | -14.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.32 | -9.33 | -10.58 | -13.02 | -14.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.32M | -9.33M | -10.58M | -13.02M | -14.65M |
| EBIT | -8.45M | -9.42M | -10.63M | -13.11M | -14.80M |
| EBITDA | -8.40M | -9.36M | -10.57M | -13.05M | -14.74M |
| EPS Basic | -75.24 | -142.79 | -209.21 | -274.56 | -329.23 |
| Normalized Basic EPS | -44.78 | -86.98 | -128.46 | -169.29 | -200.25 |
| EPS Diluted | -75.24 | -142.79 | -209.21 | -274.56 | -329.23 |
| Normalized Diluted EPS | -44.78 | -86.98 | -128.46 | -169.29 | -200.25 |
| Average Basic Shares Outstanding | 3.02M | 1.49M | 269.30K | 192.30K | 185.00K |
| Average Diluted Shares Outstanding | 3.02M | 1.49M | 269.30K | 192.30K | 185.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.07% | -0.09% | -0.08% | -0.06% | -0.05% |
